triple agonist glp 1 Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide triple agonist glp-1 gip

It doesn't take long to throw something in the blender

No effect was found, either for berberine supplements or barberries themselves

Anticancer Res 30(9):33813390 Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S, Kalaany NY, Jacks T, Chan CS, Rabinowitz JD, White E (2014) Autophagy is required for glucose homeostasis and lung tumor maintenance

Whole genome analysis and in vivo safety assessment of probiotic candidate Lactobacillus acidophilus L177

Traditional Chinese Medicine: synergistic approaches to integrative regulation and precision therapies The long-term management of diabetes typically involves the lifelong use of antidiabetic medications, which often impose economic burdens and are associated with undesirable side effects, leading to poor adherence among patients